This approval follows the priority review status by the National Medical Products Administration (“NMPA”) and marks the first nationwide regulatory approval for TAZVERIK ® in China.

China’s National Medical Products Administration (NMPA) has granted conditional approval for Hutchmed’s Tazverik (tazemetostat) to treat adults with relapsed or refractory (R/R) follicular ...

HUTCHMED has received conditional approval from the National Medical Products Administration (NMPA) in China for TAZVERIK® (tazemetostat), marking it as the first EZH2 inhibitor approved in the ...

(RTTNews) - HUTCHMED China (HCM) announced that the New Drug Application for TAZVERIK has been granted conditional approval in China for the treatment of adult patients with relapsed or refractory ...

Tazverik was approved without much fuss in the sarcoma indication, winning the backing from the FDA’s expert cancer advisers at a key meeting before Christmas.

Hutchmed (HCM) announces that the New Drug Application for Tazverik has been granted conditional approval in China for the treatment of adult patients with relapsed or refractory follicular ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 21, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the New Drug Application ("NDA” ...